DBV Technologies’ (NASDAQ:DBVT) Overweight Rating Reiterated at Morgan Stanley

Morgan Stanley reissued their overweight rating on shares of DBV Technologies S.A. (NASDAQ:DBVT) in a research report report published on Monday morning.

DBVT has been the subject of a number of other research reports. HC Wainwright reaffirmed a buy rating and set a $50.00 price objective on shares of DBV Technologies in a research note on Thursday, July 6th. Zacks Investment Research raised shares of DBV Technologies from a sell rating to a hold rating in a research note on Friday, March 31st. BidaskClub raised shares of DBV Technologies from a strong sell rating to a sell rating in a research note on Wednesday, June 21st. Deutsche Bank AG assumed coverage on shares of DBV Technologies in a research note on Friday, June 23rd. They set a buy rating and a $46.00 price objective for the company. Finally, ValuEngine raised shares of DBV Technologies from a sell rating to a hold rating in a research note on Saturday, June 24th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company. The stock has an average rating of Buy and an average target price of $47.00.

Shares of DBV Technologies (NASDAQ:DBVT) traded up 4.18% during midday trading on Monday, hitting $41.14. 75,850 shares of the stock were exchanged. The firm’s market cap is $1.89 billion. The firm has a 50-day moving average price of $34.16 and a 200 day moving average price of $34.70. DBV Technologies has a 12-month low of $31.87 and a 12-month high of $41.50.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://sportsperspectives.com/2017/07/14/dbv-technologies-nasdaqdbvt-overweight-rating-reiterated-at-morgan-stanley.html.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Victory Capital Management Inc. bought a new position in DBV Technologies during the first quarter worth approximately $303,000. DekaBank Deutsche Girozentrale bought a new position in DBV Technologies during the first quarter worth approximately $471,000. Simplex Trading LLC bought a new position in DBV Technologies during the first quarter worth approximately $526,000. Jane Street Group LLC bought a new position in DBV Technologies during the first quarter worth approximately $853,000. Finally, Bank of America Corp DE boosted its stake in shares of DBV Technologies by 86.3% in the first quarter. Bank of America Corp DE now owns 26,574 shares of the company’s stock worth $936,000 after buying an additional 12,309 shares during the last quarter. 48.23% of the stock is owned by institutional investors.

About DBV Technologies

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Analyst Recommendations for DBV Technologies (NASDAQ:DBVT)

Receive News & Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply